<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194440</url>
  </required_header>
  <id_info>
    <org_study_id>J1022</org_study_id>
    <secondary_id>SKCCC J1022</secondary_id>
    <nct_id>NCT01194440</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms</brief_title>
  <official_title>A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal
      symptoms in women receiving hormone therapy for breast cancer.

      PURPOSE: This phase II trial is studying how well zoledronic acid works in preventing
      musculoskeletal symptoms in post-menopausal women with stage I, stage II, or stage III breast
      cancer receiving letrozole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Percentage of women experiencing aromatase inhibitor associated musculoskeletal symptoms
      (AIMSS) at 1, 3, 6, and 12 months after bisphosphonate therapy, as compared to historical
      controls.

      II. Change in Health Assessment Questionnaire Disability Index (HAQ-DI) score and 1, 3, 6 and
      12 months, from baseline, among those receiving bisphosphonate, as compared to historical
      controls.

      SECONDARY OBJECTIVES:

      I. Change in pain scores on visual analog scale (VAS) at 1, 3, 6 and 12 months, from
      baseline, compared to historical controls.

      II. Change in amount and/or frequency of oral analgesic use at 1, 3, 6 and 12 months from
      baseline among those receiving bisphosphonate therapy, as compared to historical controls.

      III. Number of patients who discontinue or change aromatase inhibitor (AI) therapy.

      IV. Change in menopausal symptoms (NSABP-revised), hot flash frequency (HFRDIS),sleep quality
      (PSQI), depression score (CESD) and overall quality of life (EuroQOL) in patients at 1, 3, 6
      and 12 months from baseline, among those receiving bisphosphonate therapy, as compared to
      historical controls.

      V. Changes in plasma estrogen concentrations at 1, 3, 6 and 12 months from baseline, among
      those receiving bisphosphonate therapy, as compared to historical controls.

      VI. Change in bone mineral density (DEXA scan) at 12 months from baseline, among those
      receiving bisphosphonate therapy, as compared to historical controls.

      VII. Change in bone turn over markers (serum-C telopeptide, bone-specific alkaline
      phosphatase, osteocalcin and urinary N-telopeptide) at 1, 3, 6 and 12 months from baseline,
      among those receiving bisphosphonate therapy, as compared to historical controls.

      VIII. Change in inflammatory markers (ESR, CRP, IL-1, IL-6, IL-8) at 1, 3, 6 and 12 months
      from baseline, among those receiving bisphosphonate therapy, as compared to historical
      controls.

      OUTLINE: Patients receive zoledronic acid intravenously (IV) at months 1 and 6. Beginning 14
      days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12
      months in the absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Women With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary hypothesis of the study is that given zoledronic acid with letrozole would result in a significant decline in the percentage of women experiencing AIMSS as compared to patients receiving letrozole alone. The number of women experiencing AIMSS in this study is compared to the results from a prior published study of women receiving letrozole alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire Disability Index</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Discontinue or Change Aromatase Inhibitory (AI) Therapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Ductal Carcinoma in Situ</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Progesterone Receptor-positive Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I - IV Zoledronic Acid Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I - IV Zoledronic Acid Prophylaxis</arm_group_label>
    <other_name>CGS 20267</other_name>
    <other_name>Femara</other_name>
    <other_name>LTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I - IV Zoledronic Acid Prophylaxis</arm_group_label>
    <other_name>CGP 42446</other_name>
    <other_name>CGP42446A</other_name>
    <other_name>NDC-zoledronate</other_name>
    <other_name>ZOL 446</other_name>
    <other_name>zoledronate</other_name>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with histologically proven DCIS or stage I-III invasive carcinoma of the
             breast that is estrogen and/or progesterone receptor positive by immunohistochemical
             staining who are considering aromatase inhibitor therapy; women may receive the AI on
             this study as initial adjuvant hormonal treatment or following tamoxifen; patients
             must have completed any adjuvant chemotherapy; patients may have received preoperative
             chemotherapy

          -  Postmenopausal status, defined as: &gt;= 60 years of age; or &lt; 60 years of age and
             amenorrheic for &gt;= 12 months prior to day 1 if intact uterus/ovaries; or &lt; 60 years of
             age, and the last menstrual period 6-12 months prior to day 1, if intact
             uterus/ovaries and meets biochemical criteria for menopause (FSH and estradiol within
             institutional standards for postmenopausal status); or &lt; 60 years of age, without a
             uterus, and meets biochemical criteria for menopause (FSH and estradiol within
             institutional standards for postmenopausal status); or &lt; 60 years of age and history
             of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least
             6 months; &lt; 60 years of age and taking medication designed to suppress ovarian
             function and meets biochemical criteria for menopause (estradiol levels within
             institutional standards for postmenopausal status; women would have had to be taking
             the drug for at least 30 days prior to day 1)

          -  ECOG performance status 0-2

          -  Patient is aware of the nature of her diagnosis, understands the study regimen, its
             requirements, risks, and discomforts, and is able and willing to sign an informed
             consent form

        Exclusion Criteria

          -  Concurrent use of hormone replacement therapy

          -  Concurrent use of tamoxifen; patients taking tamoxifen must discontinue the drug prior
             to first dose of zoledronic acid

          -  Concurrent use of other selective estrogen receptor modulator (SERM) such as
             raloxifene

          -  Concurrent consumption of soy supplements; routine dietary consumption of soy
             containing foods will be permitted

          -  Prior use of an aromatase inhibitor in any setting

          -  Current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be
             eligible as long as the use was &gt; 1 month ago for oral bisphosphonates and/or &gt; 12
             months ago for intravenous bisphosphonates, prior to starting study treatment

          -  Moderate to severe renal impairment (serum creatinine greater than 2 mg/dL or
             creatinine clearance less than 50 mL/min)

          -  Hypersensitivity to letrozole or zoledronic acid or any of its excipients

          -  Concomitant treatment with oral or intravenous corticosteroids

          -  Current active dental problems including infection or the teeth or jawbone (maxilla or
             mandibular); dental or fixture trauma, or a current or prior diagnosis of
             osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after
             dental procedures

          -  Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://meetinglibrary.asco.org/record/93542/abstract</url>
    <description>General poster session - 2014 ASCO Annual Meeting</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <results_first_submitted>November 10, 2016</results_first_submitted>
  <results_first_submitted_qc>November 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2017</results_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From February 2011 to January 2013, 59 women signed consent, met eligibility criteria, and received study intervention on this clinical trial at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins.</recruitment_details>
      <pre_assignment_details>Participants were not included after consent if eligibility criteria were not met (eg, lab values, performance status); an additional 4 subjects were consented but not included in the study population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I - IV Zoledronic Acid Prophylaxis</title>
          <description>Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
letrozole: Given orally
zoledronic acid: Given IV
laboratory biomarker analysis: Correlative studies
enzyme-linked immunosorbent assay: Correlative studies
mass spectrometry: Correlative studies
bone scan: Correlative studies
quality-of-life assessment: Ancillary studies
questionnaire administration: Ancillary studies
pharmacogenomic studies: Correlative studies
high performance liquid chromatography: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
letrozole: Given orally
zoledronic acid: Given IV
laboratory biomarker analysis: Correlative studies
enzyme-linked immunosorbent assay: Correlative studies
mass spectrometry: Correlative studies
bone scan: Correlative studies
quality-of-life assessment: Ancillary studies
questionnaire administration: Ancillary studies
pharmacogenomic studies: Correlative studies
high performance liquid chromatography: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Women With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)</title>
        <description>The primary hypothesis of the study is that given zoledronic acid with letrozole would result in a significant decline in the percentage of women experiencing AIMSS as compared to patients receiving letrozole alone. The number of women experiencing AIMSS in this study is compared to the results from a prior published study of women receiving letrozole alone.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
letrozole: Given orally
zoledronic acid: Given IV
laboratory biomarker analysis: Correlative studies
enzyme-linked immunosorbent assay: Correlative studies
mass spectrometry: Correlative studies
bone scan: Correlative studies
quality-of-life assessment: Ancillary studies
questionnaire administration: Ancillary studies
pharmacogenomic studies: Correlative studies
high performance liquid chromatography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Women With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)</title>
          <description>The primary hypothesis of the study is that given zoledronic acid with letrozole would result in a significant decline in the percentage of women experiencing AIMSS as compared to patients receiving letrozole alone. The number of women experiencing AIMSS in this study is compared to the results from a prior published study of women receiving letrozole alone.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis of the study is that administration of zoledronic acid with letrozole would result in a significant decline in the percentage of women experiencing AIMSS compared to letrozole treatment alone (historical control).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Bonferonni</method>
            <method_desc>Adjusting for multiple comparisons in the analyses, a Bonferonni-corrected p-value of 0.05/5 = 0.01 to represent statistical significance was used.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire Disability Index</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Discontinue or Change Aromatase Inhibitory (AI) Therapy</title>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the 12 month intervention period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
letrozole: Given orally
zoledronic acid: Given IV
laboratory biomarker analysis: Correlative studies
enzyme-linked immunosorbent assay: Correlative studies
mass spectrometry: Correlative studies
bone scan: Correlative studies
quality-of-life assessment: Ancillary studies
questionnaire administration: Ancillary studies
pharmacogenomic studies: Correlative studies
high performance liquid chromatography: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Flu-Like Symptoms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Joint Range of Motion Decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Dryness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vered Stearns</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>443-287-6489</phone>
      <email>HopkinsBreastTrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

